Hmdb loader

HMDBP00845 (Ceramide glucosyltransferase) Metabolite Associations

Displaying metabolite protein links 101 - 108 of 108 in total
HMDB ID Name CAS NumberStructureFormula Average Mass
Monoisotopic Mass 		References
HMDB0004949Cer(d18:1/16:0)24696-26-2ThumbC34H67NO3537.9007
537.512095015		Not Available
HMDB0011759Cer(d18:0/14:0)ThumbC32H65NO3511.8634
511.496444951		Not Available
HMDB0011773Cer(d18:1/14:0)ThumbC32H63NO3509.8475
509.480794887		Not Available
HMDB0011758Cer(d18:0/12:0)ThumbC30H61NO3483.8102
483.465144823		Not Available
HMDB0004947Cer(d18:1/12:0)74713-60-3ThumbC30H59NO3481.7944
481.449494759		Not Available
HMDB0006752DihydroceramideThumbC19H39NO3329.5179
329.292994119		Not Available
HMDB0000286Uridine diphosphate glucose133-89-1ThumbC15H24N2O17P2566.3018
566.055020376		Not Available
HMDB0014563Miglustat72599-27-0ThumbC10H21NO4219.278
219.147058165
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60. [PubMed:12803929 ]
  3. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9. [PubMed:16247743 ]
  4. Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, Chen SJ, Hwu WL: Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007 Oct;30(5):826. Epub 2007 Jun 21. [PubMed:17603755 ]
  5. Treiber A, Morand O, Clozel M: The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007 Mar;37(3):298-314. [PubMed:17624027 ]
  6. Ficicioglu C: Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008 Apr;4(2):425-31. [PubMed:18728838 ]
  7. Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18. [PubMed:19956552 ]
  8. Pastores GM: Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov. 2006 Jan;1(1):77-82. [PubMed:18221193 ]
  9. McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6. [PubMed:14609352 ]
  10. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M: Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica. 2006 May;91(5):703-6. Epub 2006 Apr 19. [PubMed:16627252 ]
Displaying metabolite protein links 101 - 108 of 108 in total